お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
984841

心臓マーカー検査の世界市場 (~2025年):製品 (試薬・機器)・コンポーネント (トロポニンI&T・CK-MB・ミオグロビン・BNP・hsCRP)・疾患 (心筋梗塞・うっ血性心不全・アテローム性動脈硬化症)・エンドユーザー (ラボ・PoC・学術機関)・地域別

Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hsCRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atheresclerosis), Enduser (Lab, PoC, Academia) - Global Forecasts to 2025

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 163 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.37円
心臓マーカー検査の世界市場 (~2025年):製品 (試薬・機器)・コンポーネント (トロポニンI&T・CK-MB・ミオグロビン・BNP・hsCRP)・疾患 (心筋梗塞・うっ血性心不全・アテローム性動脈硬化症)・エンドユーザー (ラボ・PoC・学術機関)・地域別
出版日: 2021年01月19日
発行: MarketsandMarkets
ページ情報: 英文 163 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の心臓マーカー検査の市場規模は予測期間中8.9%のCAGRで推移し、2020年の36億米ドルから、2025年には55億米ドルの規模に成長すると予測されています。心血管疾患の発症率の増加、老齢人口の急激な増加、心臓バイオマーカー研究のための公的機関、民間組織からの投入資金の増加、新規心臓バイオマーカーの同定の臨床試験などの要因が同市場の成長を推進しています。一方で、サンプル回収・保管に関する技術的な課題、法規制・償還システムに関する課題などが市場のさらなる成長の妨げとなる見通しです。

当レポートでは、世界の心臓マーカー検査の市場を調査し、市場の定義と概要、バリューチェーン、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制・償還環境、ケーススタディ、市場規模の推移・予測、製品・バイオマーカータイプ・疾患・エンドユーザー・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
  • COVID-19の影響
  • 規制分析:主要国別
  • 償還シナリオ
  • バリューチェーン分析
  • 親産業のエコシステム
  • ケーススタディ

第6章 市場分析・予測:製品別

  • 試薬・キット
  • 機器
    • 化学発光
    • 免疫蛍光法
    • ELISA
    • 免疫クロマトグラフィー

第7章 市場分析・予測:バイオマーカータイプ別

  • トロポニンI・T
  • CK-MB
  • BNP・NT-PROBNP
  • ミオグロビン
  • HSCRP
  • その他

第8章 市場分析・予測:疾患別

  • 心筋梗塞
  • 鬱血性心不全
  • 急性冠症候群
  • アテローム性動脈硬化症
  • 虚血

第9章 市場分析・予測:エンドユーザー別

  • ラボ
    • 病院ラボ
    • リファレンスラボ
    • 委託ラボ
  • 学術機関
  • POC (ポイントオブケア) 検査施設

第10章 市場分析・予測:地域・主要国別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ

第11章 競合情勢

  • 戦略的概要
  • 市場シェア分析
  • 競合シナリオ
  • 主要な市場展開

第12章 企業評価マトリックス・企業プロファイル

  • 企業の評価マトリックス
  • 企業プロファイル
    • ABBOTT LABORATORIES
    • BECTON, DICKINSON AND COMPANY
    • BIOMERIEUX SA
    • BIO-RAD LABORATORIES, INC.
    • DANAHER CORPORATION
    • DIASORIN
    • F. HOFFMANN-LA ROCHE AG
    • GUANGZHOU WONDFO BIOTECH CO., LTD.
    • LSI MEDIENCE CORPORATION
    • ORTHO CLINICAL DIAGNOSTICS
    • PERKINELMER, INC.
    • RANDOX LABORATORIES
    • SIEMENS HEALTHINEERS AG
    • THERMO FISHER SCIENTIFIC
    • TOSOH CORPORATION

第13章 付録

目次
Product Code: MD 4673

The global cardiac marker testing market size is projected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2020, at a CAGR of 8.9%. The growth in the cardiac marker testing market is majorly driven by the growing incidence of cardiovascular diseases, rapidly increasing geriatric population, growing funding from public and private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers. However, factors such as technical problems related to sample collection and storage and issues related to regulatory and reimbursement systems are expected to restrain market growth to a certain extent.

The cardiac marker testing market is also faced a period of short-term negative growth, which can be attributed to factors such as a greater than 50% drop in the number of patients with cardiovascular conditions and those diagnosed with myocardial infarction. All areas of cardiology service provision sustained significant reductions, which included outpatient clinics, investigations, procedures, and cardiology community services such as cardiac rehabilitation.

"Wide use of reagents and kits in all basic diagnostic activities in laboratories, academic institutes, and POC settings is expected to result in the segment occupying the majority of the cardiac marker testing market share"

Growing number of cardiac marker testing procedures, accessibility to a wide range of cardiac biomarker reagents and kits, and the growing demand for reliable, specific, and faster detection of cardiovascular diseases at an early stage are the key growth factors for this segment.

"Troponin I and T estimated to be the fastest-growing market "

Troponin I and T is estimated to be the fastest-growing segment in the cardiac marker testing market. The large share of this segment can be attributed high sensitivity and specificity, long elevation times, and rapid prediction of outcome or mortality.

"The Asia Pacific market to grow at the highest CAGR during the forecast period"

The cardiac marker testing market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is estimated to be the fastest-growing market for cardiac marker testing during the forecast period. The Asia Pacific market is driven due increased healthcare spending by a larger population base, healthcare infrastructure modernization, and the rising penetration of cutting-edge clinical laboratory technologies (especially in rural areas) in Asia Pacific countries.

Breakdown of supply-side primary interviews:

  • By Company Type: Tier 1: 48%, Tier 2: 36%, and Tier 3: 16%
  • By Designation: C-level: 10%, D-level: 14%, and Others: 76%
  • By Region: North America: 40%, Europe: 32%, APAC: 20%, Latin America: 5%, and the Middle East & Africa: 3%

The major players operating in the cardiac marker testing market are Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Danaher Corporation (US), bioMerieux SA (France), LSI Medience Corporation (Japan), Ortho Clinical Diagnostics (US), Randox laboratories Ltd. (UK), Guangzhou Wondfo Biotech Co., Ltd (China), DiaSorin S.p.A. (Italy), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), PerkinElmer Inc. (US), Thermo Fisher Scientific Inc. (US), and Tosoh Corporation (Japan)

Research Coverage

This report studies the cardiac marker testing market based on the product, biomarker type, disease, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Key Benefits of Buying the Report

This report focuses on various levels of analysis-industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the cardiac marker testing market, and high-growth regions and their drivers, restraints, opportunities, and challenges. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY USED FOR THE STUDY
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Indicative list of secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 BREAKDOWN OF PRIMARIES: CARDIAC MARKER TESTING MARKET
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    • 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
    • 2.2.2 END USER-BASED MARKET ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: CARDIAC MARKER TESTING MARKET
    • 2.2.3 PRIMARY RESEARCH VALIDATION
  • 2.3 DATA TRIANGULATION
    • FIGURE 5 DATA TRIANGULATION METHODOLOGY
  • 2.4 RESEARCH ASSUMPTIONS
  • 2.5 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

    • FIGURE 6 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2020 VS. 2025 (USD MILLION)
    • FIGURE 7 CARDIAC MARKER TESTING MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
    • FIGURE 8 GEOGRAPHICAL SNAPSHOT OF THE CARDIAC MARKER TESTING MARKET

4 PREMIUM INSIGHTS

  • 4.1 CARDIAC MARKER TESTING MARKET OVERVIEW
    • FIGURE 9 INCREASING INCIDENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET GROWTH
  • 4.2 CARDIAC MARKER TESTING MARKET SHARE, BY PRODUCT, 2020 VS. 2025
    • FIGURE 10 REAGENTS & KITS SEGMENT WILL CONTINUE TO DOMINATE THE CARDIAC MARKER TESTING MARKET IN 2025
  • 4.3 CARDIAC MARKER TESTING MARKET, BY REGION, 2020-2025
    • FIGURE 11 APAC REGION TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 12 CARDIAC MARKER TESTING MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing incidence of cardiovascular diseases
      • 5.2.1.2 Rapidly increasing geriatric population and the subsequent increase in the burden of heart diseases worldwide
      • 5.2.1.3 Growing funding from public and private organizations for research on cardiac biomarkers
      • 5.2.1.4 Ongoing clinical trials for the identification of novel cardiac biomarkers
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Technical problems related to sample collection and storage
      • 5.2.2.2 Issues related to regulatory and reimbursement systems
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Point-of-care testing (POCT) with cardiac biomarkers
      • 5.2.3.2 Ongoing research on novel cardiac biomarkers for cardiovascular diseases
      • 5.2.3.3 Emerging markets to offer high-growth opportunities for market players
  • 5.3 COVID-19 IMPACT ON THE CARDIAC MARKER TESTING MARKET
  • 5.4 REGULATORY ANALYSIS
    • 5.4.1 US
    • TABLE 1 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
    • FIGURE 13 US: REGULATORY PROCESS FOR IVD DEVICES
    • 5.4.2 CANADA
    • FIGURE 14 CANADA: REGULATORY PROCESS FOR IVD DEVICES
    • 5.4.3 EUROPE
    • TABLE 2 EUROPE: CLASSIFICATION OF IVD DEVICES
    • FIGURE 15 EUROPE: REGULATORY PROCESS FOR IVD DEVICES
    • 5.4.4 JAPAN
    • FIGURE 16 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
    • TABLE 3 JAPAN: CLASSIFICATION OF IVD REAGENTS
    • TABLE 4 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.4.5 CHINA
    • TABLE 5 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.4.6 INDIA
    • FIGURE 17 INDIA: REGULATORY PROCESS FOR IVD DEVICES
    • 5.4.7 RUSSIA
    • TABLE 6 RUSSIA: CLASSIFICATION OF IVD DEVICES
    • 5.4.8 MEXICO
    • FIGURE 18 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
    • TABLE 7 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.4.9 BRAZIL
    • FIGURE 19 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
    • 5.4.10 SOUTH KOREA
    • TABLE 8 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • 5.5 REIMBURSEMENT SCENARIO
    • TABLE 9 REIMBURSEMENT CODES FOR VARIOUS BIOMARKERS
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 20 CARDIAC MARKER TESTING MARKET: VALUE CHAIN ANALYSIS
  • 5.7 ECOSYSTEM: PARENT INDUSTRY (IN VITRO DIAGNOSTICS)
  • 5.8 SE CASES: IN VITRO DIAGNOSTICS MARKET
    • 5.8.1 REVENUE OPPORTUNITIES: IVD ASSAY DEVELOPMENT SERVICES
    • 5.8.2 REVENUE OPPORTUNITIES: IVD CONTRACT RESEARCH SERVICES

6 CARDIAC MARKER TESTING MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 10 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • 6.2 REAGENTS & KITS
    • 6.2.1 INCREASING NUMBER OF TESTS PERFORMED TO DRIVE THE MARKET GROWTH
    • TABLE 11 CARDIAC MARKER TESTING REAGENTS AND KITS MARKET, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 12 CARDIAC MARKER TESTING REAGENTS AND KITS MARKET, BY BIOMARKER TYPE, 2018-2025 (USD MILLION)
  • 6.3 INSTRUMENTS
    • TABLE 13 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2018-2025 (USD MILLION)
    • TABLE 14 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2018-2025 (USD MILLION)
    • TABLE 15 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY REGION, 2018-2025 (USD MILLION)
    • 6.3.1 CHEMILUMINESCENCE
      • 6.3.1.1 Chemiluminescence is the most preferred method for the quantification of cardiac biomarkers
    • TABLE 16 CARDIAC MARKER TESTING INSTRUMENTS MARKET FOR CHEMILUMINESCENCE, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 17 CARDIAC MARKER TESTING INSTRUMENTS MARKET FOR CHEMILUMINESCENCE, BY BIOMARKER TYPE, 2018-2025 (USD MILLION)
    • 6.3.2 IMMUNOFLUORESCENCE
      • 6.3.2.1 Demand for stable and safer reagents to support market growth
    • TABLE 18 CARDIAC MARKER TESTING INSTRUMENTS MARKET FOR IMMUNOFLUORESCENCE, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 19 CARDIAC MARKER TESTING INSTRUMENTS MARKET FOR IMMUNOFLUORESCENCE, BY BIOMARKER TYPE, 2018-2025 (USD MILLION)
    • 6.3.3 ELISA
      • 6.3.3.1 Ease of use and simplicity of the method are the key advantages associated with ELISA
    • TABLE 20 CARDIAC MARKER TESTING INSTRUMENTS MARKET FOR ELISA, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 21 CARDIAC MARKER TESTING INSTRUMENTS MARKET FOR ELISA, BY BIOMARKER TYPE, 2018-2025 (USD MILLION)
    • 6.3.4 IMMUNOCHROMATOGRAPHY
      • 6.3.4.1 Increasing use in point-of-care settings to fuel the adoption of this technique
    • TABLE 22 CARDIAC MARKER TESTING INSTRUMENTS MARKET FOR IMMUNOCHROMATOGRAPHY, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 23 CARDIAC MARKER TESTING INSTRUMENTS MARKET FOR IMMUNOCHROMATOGRAPHY, BY BIOMARKER TYPE, 2018-2025 (USD MILLION)

7 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE

  • 7.1 INTRODUCTION
    • TABLE 24 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2018-2025 (USD MILLION)
  • 7.2 TROPONIN I AND T
    • 7.2.1 HIGH SENSITIVITY OF THIS BIOMARKER TEST IS SUPPORTING ITS INCREASED ADOPTION IN THE MARKET
    • TABLE 25 CHARACTERISTICS OF TROPONIN CARDIAC MARKERS
    • TABLE 26 CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 27 CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY DISEASE, 2018-2025 (USD MILLION)
    • TABLE 28 CARDIAC MARKER TESTING MARKET FOR TROPONIN I AND T, BY END USER, 2018-2025 (USD MILLION)
  • 7.3 CK-MB
    • 7.3.1 CK-MB IS USEFUL FOR THE DIAGNOSIS OF ACUTE MYOCARDIAL INJURY
    • TABLE 29 CHARACTERISTICS OF CK-MB CARDIAC MARKERS
    • TABLE 30 CARDIAC MARKER TESTING MARKET FOR CK-MB, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 31 CARDIAC MARKER TESTING MARKET FOR CK-MB, BY DISEASE, 2018-2025 (USD MILLION)
    • TABLE 32 CARDIAC MARKER TESTING MARKET FOR CK-MB, BY END USER, 2018-2025 (USD MILLION)
  • 7.4 BNP AND NT-PROBNP
    • 7.4.1 THE ABILITY OF THIS BIOMARKER TO BE USED WITH OTHER MARKERS IS SUPPORTING MARKET GROWTH
    • TABLE 33 CARDIAC MARKER TESTING MARKET FOR BNP AND NT-PROBNP, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 34 CARDIAC MARKER TESTING MARKET FOR BNP AND NT-PROBNP, BY DISEASE, 2018-2025 (USD MILLION)
    • TABLE 35 CARDIAC MARKER TESTING MARKET FOR BNP AND NT-PROBNP, BY END USER, 2018-2025 (USD MILLION)
  • 7.5 MYOGLOBIN
    • 7.5.1 RAPID INCREASE AND NORMALIZATION ASSOCIATED WITH MYOGLOBIN TO DRIVE MARKET GROWTH
    • TABLE 36 CHARACTERISTICS OF MYOGLOBIN CARDIAC MARKERS
    • TABLE 37 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 38 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY DISEASE, 2018-2025 (USD MILLION)
    • TABLE 39 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY END USER, 2018-2025 (USD MILLION)
  • 7.6 HSCRP
    • 7.6.1 ABILITY OF HSCRP TESTS TO ACCURATELY MEASURE LOW LEVELS OF CRP WILL SUPPORT MARKET GROWTH
    • TABLE 40 CUT-OFFS FOR CRP USING STANDARDIZED ASSAY
    • TABLE 41 CARDIAC MARKER TESTING MARKET FOR HSCRP, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 42 CARDIAC MARKER TESTING MARKET FOR HSCRP, BY DISEASE, 2018-2025 (USD MILLION)
    • TABLE 43 CARDIAC MARKER TESTING MARKET FOR HSCRP, BY END USER, 2018-2025 (USD MILLION)
  • 7.7 OTHER BIOMARKERS
    • TABLE 44 CARDIAC MARKER TESTING MARKET FOR OTHER BIOMARKERS, BY REGION, 2018-2025 (USD MILLION)
    • TABLE 45 CARDIAC MARKER TESTING MARKET FOR OTHER BIOMARKERS, BY DISEASE, 2018-2025 (USD MILLION)
    • TABLE 46 CARDIAC MARKER TESTING MARKET FOR OTHER BIOMARKERS, BY END USER, 2018-2025 (USD MILLION)

8 CARDIAC MARKER TESTING MARKET, BY DISEASE

  • 8.1 INTRODUCTION
    • TABLE 47 CARDIAC MARKER TESTING MARKET, BY DISEASE, 2018-2025 (USD MILLION)
  • 8.2 MYOCARDIAL INFARCTION
    • 8.2.1 AVAILABILITY OF HIGH-SENSITIVITY BIOMARKERS FOR THE DETECTION OF MI TO SUPPORT MARKET GROWTH
    • TABLE 48 CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2018-2025 (USD MILLION)
  • 8.3 CONGESTIVE HEART FAILURE
    • 8.3.1 GROWING USE OF MULTI-MARKER TESTING IS DRIVING MARKET GROWTH
    • TABLE 49 CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2018-2025 (USD MILLION)
  • 8.4 ACUTE CORONARY SYNDROME
    • 8.4.1 INCREASING INCIDENCE OF RISK FACTORS ASSOCIATED WITH ACS TO DRIVE THE ADOPTION OF CARDIAC MARKERS
    • TABLE 50 CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2018-2025 (USD MILLION)
  • 8.5 ATHEROSCLEROSIS
    • 8.5.1 HIGH PREVALENCE OF ATHEROSCLEROSIS WILL PROPEL THE ADOPTION OF CARDIAC MARKERS
    • TABLE 51 CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 2018-2025 (USD MILLION)
  • 8.6 ISCHEMIA
    • 8.6.1 MULTIPLE COMPLICATIONS CAUSED BY ISCHEMIA IS RESULTING IN THE INCREASED ADOPTION OF DIAGNOSTICS TESTS
    • TABLE 52 CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY REGION, 2018-2025 (USD MILLION)

9 CARDIAC MARKER TESTING MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 53 CARDIAC MARKER TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 9.2 LABORATORY TESTING FACILITIES
    • TABLE 54 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 55 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY REGION, 2018-2025 (USD MILLION)
    • 9.2.1 HOSPITAL LABORATORIES
      • 9.2.1.1 Emergency patient care and early diagnosis associated with in-house labs to drive market growth
    • TABLE 56 CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2018-2025 (USD MILLION)
    • 9.2.2 REFERENCE LABORATORIES
      • 9.2.2.1 Cost and time savings associated with reference laboratories to support market growth
    • TABLE 57 CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY REGION, 2018-2025 (USD MILLION)
    • 9.2.3 CONTRACT TESTING LABORATORIES
      • 9.2.3.1 Access to a wide range of tests in such settings allows multiple tests to be performed
    • TABLE 58 CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY REGION, 2018-2025 (USD MILLION)
  • 9.3 ACADEMIC INSTITUTES
    • 9.3.1 CONTINUOUS RESEARCH & DEVELOPMENT OF NOVEL BIOMARKERS TO DRIVE MARKET GROWTH
    • TABLE 59 CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2018-2025 (USD MILLION)
  • 9.4 POINT-OF-CARE TESTING FACILITIES
    • 9.4.1 EARLY DETECTION AND LOWER TURNAROUND TEST TIME WILL DRIVE MARKET GROWTH
    • TABLE 60 CARDIAC MARKER TESTING MARKET FOR POC TESTING FACILITIES, BY REGION, 2018-2025 (USD MILLION)

10 CARDIAC MARKER TESTING MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 61 CARDIAC MARKER TESTING MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 21 NORTH AMERICA: CARDIAC MARKER TESTING MARKET SNAPSHOT
    • TABLE 62 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 63 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2018-2025 (USD MILLION)
    • TABLE 64 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 65 NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 66 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 Increasing public-private investments for cardiac biomarker research to drive market growth
    • TABLE 67 US: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Increasing government initiatives to support the cardiac marker testing market in Canada
    • TABLE 68 CANADA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 69 EUROPE: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 70 EUROPE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2018-2025 (USD MILLION)
    • TABLE 71 EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 72 EUROPE: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 73 EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Higher healthcare spending to fuel diagnostic testing
    • TABLE 74 GERMANY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 Increasing number of accredited clinical laboratories to increase the adoption of cardiac marker tests in the country
    • TABLE 75 UK: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Increasing demand for early disease diagnosis to drive market growth
    • TABLE 76 FRANCE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • 10.3.4 ITALY
      • 10.3.4.1 Increasing prevalence of chronic and infectious diseases to drive market growth
    • TABLE 77 ITALY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • 10.3.5 SPAIN
      • 10.3.5.1 Rising geriatric population in the country to support market growth
    • TABLE 78 SPAIN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • 10.3.6 REST OF EUROPE (ROE)
    • TABLE 79 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 22 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET SNAPSHOT
    • TABLE 80 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 81 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2018-2025 (USD MILLION)
    • TABLE 82 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 83 ASIA PACIFIC: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 84 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 10.4.1 JAPAN
      • 10.4.1.1 Presence of a well-developed healthcare system to drive market growth in Japan
    • TABLE 85 JAPAN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 Increasing disposable income of the Chinese population to fuel market growth
    • TABLE 86 CHINA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Presence of a large patient population to fuel the demand for cardiac marker testing in the country
    • TABLE 87 INDIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • 10.4.4 SOUTH KOREA
      • 10.4.4.1 Growing number of private hospitals and independent testing laboratories to drive market growth
    • TABLE 88 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • 10.4.5 AUSTRALIA
      • 10.4.5.1 High healthcare expenditure in the country to support market growth
    • TABLE 89 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • 10.4.6 REST OF ASIA PACIFIC (ROAPAC)
    • TABLE 90 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • 10.5 LATIN AMERICA
    • TABLE 91 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 92 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2018-2025 (USD MILLION)
    • TABLE 93 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 94 LATIN AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 95 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 10.5.1 BRAZIL
      • 10.5.1.1 Rising investments by leading IVD manufacturers in the country to drive market growth
    • TABLE 96 BRAZIL: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • 10.5.2 MEXICO
      • 10.5.2.1 Availability of technologically advanced IVD products in the country to propel market growth
    • TABLE 97 MEXICO: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • 10.5.3 REST OF LATIN AMERICA
    • TABLE 98 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET GROWTH
    • TABLE 99 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2018-2025 (USD MILLION)
    • TABLE 100 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
    • TABLE 101 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION)
    • TABLE 102 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2018-2025 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 STRATEGIC OVERVIEW
    • FIGURE 23 KEY DEVELOPMENTS IN THE CARDIAC MARKER TESTING MARKET, 2017- 2020
  • 11.3 MARKET SHARE ANALYSIS
    • FIGURE 24 CARDIAC MARKER TESTING MARKET SHARE, BY KEY PLAYER, 2019
  • 11.4 COMPETITIVE SCENARIO
  • 11.5 KEY MARKET DEVELOPMENTS
    • 11.5.1 PRODUCT LAUNCHES AND APPROVALS
    • 11.5.2 ACQUISITIONS
    • 11.5.3 PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS
    • 11.5.4 EXPANSIONS

12 COMPANY EVALUATION MATRIX AND COMPANY PROFILES

  • 12.1 COMPANY EVALUATION MATRIX
    • 12.1.1 STARS
    • 12.1.2 EMERGING LEADERS
    • 12.1.3 EMERGING COMPANIES
    • 12.1.4 PERVASIVE
    • FIGURE 25 CARDIAC MARKER TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019
  • 12.2 COMPANY PROFILES
  • (Business overview, Products offered, Recent developments, MNM view)**
    • 12.2.1 ABBOTT LABORATORIES
    • FIGURE 26 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019)
    • 12.2.2 BECTON, DICKINSON AND COMPANY
    • FIGURE 27 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2019)
    • 12.2.3 BIOMERIEUX SA
    • FIGURE 28 BIOMERIEUX SA: COMPANY SNAPSHOT (2019)
    • 12.2.4 BIO-RAD LABORATORIES, INC.
    • FIGURE 29 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2019)
    • 12.2.5 DANAHER CORPORATION
    • FIGURE 30 DANAHER CORPORATION: COMPANY SNAPSHOT (2019)
    • 12.2.6 DIASORIN
    • FIGURE 31 DIASORIN: COMPANY SNAPSHOT (2019)
    • 12.2.7 F. HOFFMANN-LA ROCHE AG
    • FIGURE 32 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2019)
    • 12.2.8 GUANGZHOU WONDFO BIOTECH CO., LTD.
    • 12.2.9 LSI MEDIENCE CORPORATION
    • FIGURE 33 MITSUBISHI CHEMICAL HOLDINGS CORPORATION: COMPANY SNAPSHOT (2019)
    • 12.2.10 ORTHO CLINICAL DIAGNOSTICS
    • 12.2.11 PERKINELMER, INC.
    • FIGURE 34 PERKINELMER: COMPANY SNAPSHOT (2019)
    • 12.2.12 RANDOX LABORATORIES
    • 12.2.13 SIEMENS HEALTHINEERS AG
    • FIGURE 35 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2019)
    • 12.2.14 THERMO FISHER SCIENTIFIC
    • FIGURE 36 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019)
    • 12.2.15 TOSOH CORPORATION
    • FIGURE 37 TOSOH CORPORATION: COMPANY SNAPSHOT (2019)
  • *Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.